Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Matsumoto, Kinnosuke; Shiroyama, Takayuki; Tamiya, Motohiro; Minami, Toshiyuki; Kinehara, Yuhei; Tamiya, Akihiro; Suga, Yasuhiko; Kuge, Tomoki; Mori, Masahide; Suzuki, Hidekazu; Tobita, Satoshi; Ueno, Kiyonobu; Namba, Yoshinobu; Tetsumoto, Satoshi; Niki, Toshie; Morimura, Osamu; Osa, Akio; Nishino, Kazumi; Nagatomo, Izumi; Takeda, Yoshito; Kijima, Takashi; Kumanogoh, Atsushi

doi:https://doi.org/10.1007/s00262-023-03583-4

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Matsumoto, Kinnosuke; Shiroyama, Takayuki; Tamiya, Motohiro et al.

Cancer Immunology, Immunotherapy, 2024, 73(4)

Number of Access:1,956（2025-07-18 09:47 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93547

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
CancerImmunolImmunother_73_4	pdf	None	1.80 MB	91	2024.02.01

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
Creator	CreatorName Matsumoto, Kinnosuke
	NRID 1000060860062 1000060860062 researchmap permalink shiroyama_t shiroyama_t Scopus Author ID 36476578400 36476578400 CreatorName Shiroyama, Takayuki
	CreatorName Tamiya, Motohiro
	NRID 1000000705113 1000000705113 CreatorName Minami, Toshiyuki
	CreatorName Kinehara, Yuhei
	CreatorName Tamiya, Akihiro
	NRID 1000060895069 1000060895069 researchmap permalink yasu031055- yasu031055- CreatorName Suga, Yasuhiko
	CreatorName Kuge, Tomoki
	CreatorName Mori, Masahide
	CreatorName Suzuki, Hidekazu
	CreatorName Tobita, Satoshi
	CreatorName Ueno, Kiyonobu
	CreatorName Namba, Yoshinobu
	CreatorName Tetsumoto, Satoshi
	CreatorName Niki, Toshie
	CreatorName Morimura, Osamu
	NRID 1000020751390 1000020751390 CreatorName Osa, Akio
	CreatorName Nishino, Kazumi
	NRID 1000010570583 1000010570583 researchmap permalink saxon-w saxon-w Scopus Author ID 13404305500 13404305500 CreatorName Nagatomo, Izumi
	NRID 1000040452388 1000040452388 researchmap permalink yoshi10 yoshi10 Scopus Author ID 7404001848 7404001848 CreatorName Takeda, Yoshito
	NRID 1000090372614 1000090372614 CreatorName Kijima, Takashi
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 CreatorName Kumanogoh, Atsushi
Subject	Ipilimumab
	Nivolumab
	Non-small-cell Lung cancer
	Pembrolizumab
	Propensity score
	Real-world
Description	The version of record of this article, first published in Cancer Immunology, Immunotherapy, is available online at Publisher’s website: https://doi.org/10.1007/s00262-023-03583-4
Abstract	Introduction: Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). Compared with immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy can increase immune-related toxicity instead of prolonging survival. This study aimed to compare the efficacy and safety of NICT and PCT to decide on the favorable treatment. Methods: We conducted a multi-center retrospective cohort study on patients who underwent NICT or PCT between December 2018 and May 2022. Propensity score matching (PSM) was performed with the variables age, sex, smoking status, performance status, stage, histology, and programmed cell death ligand-1 (PD-L1). The Kaplan–Meier method was used to compare survival for the matched patients. Results: Six hundred consecutive patients were included. After PSM, 81 and 162 patients were enrolled in the NICT and PCT groups, respectively. The baseline characteristics were well-balanced. The median progression-free survival was equivalent (11.6 vs. 7.4 months; P = 0.582); however, the median overall survival (OS) was significantly longer in the NICT group than in the PCT group (26.0 vs. 16.8 months; P = 0.005). Furthermore, OS was better in PD-L1-negative patients who underwent NICT than in those who underwent PCT (26.0 vs. 16.8 months; P = 0.045). Safety profiles did not differ significantly in terms of severe adverse event and treatment-related death rates (P = 0.560, and 0.722, respectively). Conclusions: Real-world data suggests that NICT could be a favorable treatment option compared with PCT for patients with advanced NSCLC. Further follow-up is needed to determine the long-term prognostic benefit.
Publisher	Springer Science and Business Media Deutschland GmbH
Source Title	Cancer Immunology, Immunotherapy
Volume (Issue)	73(4)
Date of Issued	2024-01-04
Language	English
Handle URL	https://hdl.handle.net/11094/93547
PISSN	03407004
eISSN	14320851
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s00262-023-03583-4
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Cancer Immunology, Immunotherapy. 2024, 73(4)
DC.title	Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
DC.creator	Matsumoto, Kinnosuke
	Shiroyama, Takayuki
	Tamiya, Motohiro
	Minami, Toshiyuki
	Kinehara, Yuhei
	Tamiya, Akihiro
	Suga, Yasuhiko
	Kuge, Tomoki
	Mori, Masahide
	Suzuki, Hidekazu
	Tobita, Satoshi
	Ueno, Kiyonobu
	Namba, Yoshinobu
	Tetsumoto, Satoshi
	Niki, Toshie
	Morimura, Osamu
	Osa, Akio
	Nishino, Kazumi
	Nagatomo, Izumi
	Takeda, Yoshito
	Kijima, Takashi
	Kumanogoh, Atsushi
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-01-04
DC.identifier	https://doi.org/10.1007/s00262-023-03583-4
DC.subject	Ipilimumab
	Nivolumab
	Non-small-cell Lung cancer
	Pembrolizumab
	Propensity score
	Real-world
DC.description	The version of record of this article, first published in Cancer Immunology, Immunotherapy, is available online at Publisher’s website: https://doi.org/10.1007/s00262-023-03583-4
DCTERMS.abstract	Introduction: Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). Compared with immune checkpoint inhibitor (ICI) monotherapy, ICI combination therapy can increase immune-related toxicity instead of prolonging survival. This study aimed to compare the efficacy and safety of NICT and PCT to decide on the favorable treatment. Methods: We conducted a multi-center retrospective cohort study on patients who underwent NICT or PCT between December 2018 and May 2022. Propensity score matching (PSM) was performed with the variables age, sex, smoking status, performance status, stage, histology, and programmed cell death ligand-1 (PD-L1). The Kaplan–Meier method was used to compare survival for the matched patients. Results: Six hundred consecutive patients were included. After PSM, 81 and 162 patients were enrolled in the NICT and PCT groups, respectively. The baseline characteristics were well-balanced. The median progression-free survival was equivalent (11.6 vs. 7.4 months; P = 0.582); however, the median overall survival (OS) was significantly longer in the NICT group than in the PCT group (26.0 vs. 16.8 months; P = 0.005). Furthermore, OS was better in PD-L1-negative patients who underwent NICT than in those who underwent PCT (26.0 vs. 16.8 months; P = 0.045). Safety profiles did not differ significantly in terms of severe adverse event and treatment-related death rates (P = 0.560, and 0.722, respectively). Conclusions: Real-world data suggests that NICT could be a favorable treatment option compared with PCT for patients with advanced NSCLC. Further follow-up is needed to determine the long-term prognostic benefit.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93547
citation_title	Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
citation_author	Matsumoto, Kinnosuke
	Shiroyama, Takayuki
	Tamiya, Motohiro
	Minami, Toshiyuki
	Kinehara, Yuhei
	Tamiya, Akihiro
	Suga, Yasuhiko
	Kuge, Tomoki
	Mori, Masahide
	Suzuki, Hidekazu
	Tobita, Satoshi
	Ueno, Kiyonobu
	Namba, Yoshinobu
	Tetsumoto, Satoshi
	Niki, Toshie
	Morimura, Osamu
	Osa, Akio
	Nishino, Kazumi
	Nagatomo, Izumi
	Takeda, Yoshito
	Kijima, Takashi
	Kumanogoh, Atsushi
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	English
citation_date	2024-01-04
citation_journal_title	Cancer Immunology, Immunotherapy
citation_volume	73
citation_issue	4
citation_doi	https://doi.org/10.1007/s00262-023-03583-4
citation_public_url	https://hdl.handle.net/11094/93547

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Link to primary information

Item Information

Show details